Table 3.
Different newly developed potential vaccine candidates against SARS-CoV-2 completed phase-I or phase-II trials
| Clinical trials for COVID-19 |
|||||||
|---|---|---|---|---|---|---|---|
| Vaccine candidates | Technology | Target | Identifier ID | Phase | Participants | Location | Duration |
| Ad5-nCoV | recombinant adenovirus type 5 vector | Spike | NCT04341389 | Phase II interventional trial for dosing and side effects | 500 | China | March 2020 to December 2020 |
| Ad5-nCoV | recombinant adenovirus type 5 vector | Spike | NCT04313127 | Phase I | 108 | China | March 2020 to December 2020 |
| BNT162 (a1, b1, b2, c2) | RNA | 3CLpro, NSP5, Mpro, others | EudraCT No: 2020–001038-36 | Phase I–II of four vaccines, dose escalation, parallel cohorts | 196 | Germany | April 2020 to May 2021 |
| ChAdOx1 nCoV-19/AZD1222 | adenovirus vector | Spike |
NCT04324606 NCT04444674 NCT04536051 |
Phase I–II and III randomized, placebo-controlled, multiple sites | 510 | United Kingdom, South Africa, Brazil | April 2020 to May 2021 |
| INO-4800 | DNA plasmid transported by electroporation | Spike | NCT04336410 | Phase I–II | 140 | United States, South Korea | April 2020 to November 2020 |
| mRNA-1273 | lipid nanoparticle dispersion containing messenger RNA | Spike | NCT04283461 | Phase I | 45 | United States | March 2020 to Spring-Summer 2021 |
| Covid-19/aAPC | lentiviral vector, pathogen-specific artificial antigen presenting dendritic cells | Spike | NCT04299724 | Phase I | 100 | China | March 2020 to 2023 |
| LV-SMENP-DC | lentiviral minigene vaccine, dendritic cells modified with lentiviral vector | Undisclosed | NCT04276896 | Phase I | 100 | China | March 2020 to 2023 |
| bacTRL-Spike | DNA, bacterial medium (oral) | Spike | NCT04334980 | Phase I | 84 | Canada | April 2020 to December 2021 |
| unnamed | inactivated SARS-CoV-2 virus | Whole virus | NCT04352608 | Phase I–II randomized, double-blinded, single-center, placebo-controlled | 744 | China | April 2020 to December 2020 |
| unnamed | inactivated COVID-19 virus (vero cells) | Undisclosed | ChiCTR2000031809 | Phase I | 288 | China | April 2020 to November 2021 |